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A B S T R A C T
Plasma fibrinogen (F1) and fibronectin (pFN) polymerize to form a fibrin clot that is both a hemostatic and
provisional matrix for wound healing. About 90% of plasma F1 has a homodimeric pair of γ chains (γγF1), and
10% has a heterodimeric pair of γ and more acidic γ′ chains (γγ′F1). We have synthesized a novel fibrin matrix
exclusively from a 1:1 (molar ratio) complex of γγ′F1 and pFN in the presence of highly active thrombin and
recombinant Factor XIII (rFXIIIa). In this matrix, the fibrin nanofibers were decorated with pFN nanoclusters
(termed γγ′F1:pFN fibrin). In contrast, fibrin made from 1:1 mixture of γγF1 and pFN formed a sporadic dis-
tribution of “pFN droplets” (termed γγF1+pFN fibrin). The γγ′F1:pFN fibrin enhanced the adhesion of primary
human umbilical vein endothelium cells (HUVECs) relative to the γγF1+FN fibrin. Three dimensional (3D)
culturing showed that the γγ′F1:pFN complex fibrin matrix enhanced the proliferation of both HUVECs and
primary human fibroblasts. HUVECs in the 3D γγ′F1:pFN fibrin exhibited a starkly enhanced vascular mor-
phogenesis while an apoptotic growth profile was observed in the γγF1+pFN fibrin. Relative to γγF1+pFN
fibrin, mouse dermal wounds that were sealed by γγ′F1:pFN fibrin exhibited accelerated and enhanced healing.
This study suggests that a 3D pFN presentation on a fibrin matrix promotes wound healing.
1. Introduction
Skin wound healing consists of four phases: hemostasis, inflamma-
tion, proliferation, and remodeling. After an injury in healthy people,
plasma fibrinogen (F1) and plasma fibronectin (pFN) (10:1 at M ratio)
are polymerized by thrombin and factor XIII (FXIII) to form a fibrin clot
to stop bleeding (i.e., the hemostasis) [1]. In the clot, fibronectins are
attached covalently to the fibrin nanofibers [2]. In a material sense, F1
and pFN are both diverse macromolecules that greatly contrast each
other in structure. F1 is a linear, hexameric, 340 kDa glycoprotein
having two alpha, two beta, and two gamma chains [3–5]. pFN is a
440 kDa globular protein having two chains with cellular binding do-
mains. Both F1 and pFN have cellular binding domains that remain
cryptic until crosslinking by activated Factor XIII (FXIIIa) into the fibrin
matrix [6]. About 90% of F1 circulates as a homodimeric pairing of γ-
chains (γγ F1) while the remaining 10% presents a heterodimeric
pairing of γ with a more acidic γ′-chain (γγ′F1)[6]. The γ′-chain occurs
from an alternative transcript having 20 additional amino acids at the
carboxy-terminal that has been correlated with a pleiotropic impact on
vascular health [6–8]. Importantly, pFN and γγ′F1 both occur at about
the same concentration in plasma of about 300 μg/mL [7–11] and,
therefore, their presence in fibrin clots.
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The hemostasis begins with thrombin-mediated activation of F1 and
FXIII. The activated F1 produces a semi-soluble, viscoelastic fibrin ag-
gregate [3,12,13] containing pFN entrained from plasma. The FXIII is
inherently present within the polymerizing fibrin aggregate as a com-
plex with 1 out of every 100 γγ′F1 molecules [7]. It disassociates upon
the formation of activated FXIII that enables efficient intra-fibrin cross-
linking activity to produce an insoluble fibrin matrix [14–18], and to
simultaneously anchor the matrix to the wound surface in about 3 min
[7,19]. This clotting process causes protein conformational changes
that induce interactions between pFN, fibrin, and also wound healing
cells.
After hemostasis, the fibrin clot acts as a provisional matrix for
different cell types to heal the wound [20]. Neutrophils and in-
flammatory (or M1) macrophages first enter the matrix to clear bacteria
and tissue debris. Neutrophils secrete anti-microbial peptides, proteases
and reactive oxygen species (ROS) to remove bacteria and damaged
tissue [21]. These chemicals are toxic to surrounding healthy cells as
well [21]. The M1 macrophages phagocytosis bacterial and damaged
tissue [22–30]. Both cell types directly bind to fibrin nanofibers via
their αMβ2 integrin receptors. Once the wound is debrided (takes ~3
days [31]), neutrophils undergo apoptosis, and M1 macrophages switch
to the regenerative M2 phenotype that secretes cytokines and growth
factors to recruit and stimulate healing cells such as endothelial cells,
fibroblasts and keratinocytes to heal the wound (i.e., the proliferation
phase) [32–34]. Endothelial cells form new blood vessels, and fibro-
blasts deposit new extracellular matrix proteins to form a granulation
tissue (takes ~7 days) [32–34]. Keratinocytes migrate on the granula-
tion tissue to form a new epidermis to close the wound (i.e., re-epi-
thelization) [33]. Healing cells adhere to the fibrin matrix by binding to
fibronectins with their integrin receptors [32–35]. The binding also
triggers downstream signalings that are required for these cells to mi-
grate, proliferate, and repair the wound [32–36]. Fibronectins also
bind, enrich, protect, orientate, and present growth factors locally to
potentiate their functions [37–48]. In short, the fibrin-based provisional
matrix is the central stage for cells to heal a wound, and fibronectins are
essential for adhering and stimulating the healing cells. Consequently,
insufficient provisional matrix or fibronectins or fibronectin-induced
cell signalings lead to pathological wound healings [32–35,37]. For
instance, small wounds can heal in about 14 days, while large wounds
take much longer time to heal partially due to the insufficient fibrin-
fibronectin provisional matrix.
We hypothesize that increasing the pFN content or FN-cell inter-
action in the fibrin matrix will promote wound healing via enhancing
the migration, proliferation, and function of healing cells. The natural
fibrin matrix only contains 10% (molar ratio) fibronectins [1]. Pre-
viously, we reported a novel method to increase the pFN content up to
50% (molar ratio) in the fibrin matrix and to present the pFN as na-
noclusters on the fibrin nanofibers [8]. In this report, we showed that
this novel pFN: γγ′F1 fibrin enhanced the adhesion, proliferation, and
morphogenesis of healing cells in vitro, and accelerated re-epitheliza-
tion and granulation tissue formation in mouse dermal wounds. This
engineered fibrin sealant has attributes useful to both hemostasis and to
promote faster wound healing, including improvement of granulation
tissue quality.
Fibrin sealants using fibrinogen purified from human plasma are
commercially available for various biomedical applications such as
hemostat, tissue sealant, and tissue adhesive [49,50]. They are also
widely used for tissue engineering, and drug and cell delivery. How-
ever, studies on using purified fibrin sealant alone to enhance wound
healing are limited [51–54]. The outcomes are positive but inconsistent
and limited. Research showed cells did not infiltrate the topically ap-
plied fibrin sealant in rodent skin wounds [55]. Instead, cells migrated
underneath the sealant. The limited success may because fibrin sealants
typically use high fibrinogen concentrations (e.g.,> 25 mg/mL). The
resultant fibrin matrices have large and dense fibrin fibers that prevent
cell infiltration and proliferation [56]. Additionally, the fibronectin
content and presentation in the matrices are not defined. Some studies
use fibronectin-deprived sealants. Others use sealants that contain small
amounts of fibronectin (1 fibronectin per 10 fibrinogens). Our sealant is
novel and different from these commercial fibrin sealant. First, it has
low protein concentrations (< 9 mg/mL), and the resultant matrix has
similar micro- and nano-structures to the natural fibrin provisional
matrix. Second, it contains high fibronectin content (e.g., 1 fibronectin




All reagents were obtained from Sigma Chemical Company (St.
Louis MO) unless otherwise noted. Human source plasma was provided
by the U.S. Army Materials Command (Fort Detrick, MD.). Recombinant
human thrombin was purchased from ZymoGenetics (Seattle, WA).
DEAE Sepharose fast flow, Superose 6, and Gelatin Sepharose were
purchased from GE Healthcare (Uppsala, Sweden). 4–12% NuPage Bis-
Tris SDS polyacrylamide gels, Colloidal Blue stain, and See Blue mo-
lecular weight markers were from Invitrogen (Carlsbad, CA). Polyclonal
antibody (GMA-034) for human fibrinogen was purchased from Green
Mountain Antibodies (Burlington, VT). Antibody (ab2413) for human
fibronectin was from Abcam.
2.2. Production of recombinant factor XIII
Recombinant active Factor XIII (rFXIIIa) was expressed in Pichia
Pastoris following published methods [56–58]. The activity was de-
termined using Pefakit (Pentapharm, Norwalk, CT).
2.3. Preparation of fibrinogen and fibronectin from human plasma [8]
Three units of human plasma that had been stored at −80 °C were
thawed at 4 °C. The plasma was centrifuged at 4000 rpm for 20 min.
The cryoprecipitate was re-suspended in 45 mM sodium citrate,
100 mM 6-aminocaproic acid, pH 7.0 at 37 °C. The solution was then
centrifuged for 25 min at 4000 rpm. The supernatant was treated with a
solvent detergent to inactivate the virus by addition of 0.15% TnBP,
0.5% Triton X-100 and stirred at room temperature for 60 min. The
supernatant was adjusted to 1 M ammonium sulfate. The sample was
stirred at room temperature for 30 min and then centrifuged at
2000 rpm for 15 min at room temperature. The pellet was re-suspended
in 20 mM sodium citrate, 100 mM NaCl. The sample was dialyzed
overnight at room temperature against the same buffer. The dialyzed
sample was centrifuged at 2000 rpm for 15 min at room temperature.
The supernatant was fractionated to isolate γγF1, γγ′F1 and pFN
using DEAE Sepharose Fast Flow chromatography at room temperature
[59]. The sample was applied to a DEAE column then washed with 10
column volumes of 20 mM sodium citrate, 100 mM NaCl, pH 7.4. The
unabsorbed fraction was γγF1. Bound protein was eluted with a linear
gradient of 0.1 M–1.0 M NaCl. The pooled eluate produced an ap-
proximately equimolar mixture of γγ′F1 and pFN that was dialyzed
against 20 mM citrate buffer, 20 mM NaCl at pH 6.8. The dialyzed
mixture was concentrated using a 10 kDa centrifugal ultrafiltration
device at 4000 g for 30 min.
Pure pFN and γγ′F1 were produced by application of the DEAE el-
uate pool to gelatin-Sepharose. Briefly, a 10 mL γγ′F1:pFN (“γγ’F1:pFN”
that we will name from here as “complex”) was applied to a 3 mL
analytical gelatin-Sepharose column. The column was washed with
10 vol of the dialysis buffer then eluted with the same buffer containing
6 M urea. pFN was eluted by urea while the γγ′F1 fell through the
column.
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2.4. 2D adhesion assay
Human foreskin fibroblasts were isolated and cultured in DMEM
with 10% FBS. The use of primary human fibroblasts from anonymous
donors was approved by the Institutional Review Board at the
University of Nebraska Medical Center and by the Research and
Development Committee at the Omaha VA Medical Center. Passage 4 to
6 cells were used. HUEVCs were purchased from Lonza and cultured in
EGM2 medium. Passage 3 and 4 cells were used for the experiments.
100 μl fibrin matrix was made in one well of the 96-well plate.
1 × 104 cells were placed in each well with 200 μl medium. Three
hours after plating, medium, and unattached cells were removed. Cells
were washed with 200 μl PBS once. 100 μl fresh medium with 10 μl
Alamar blue reagent was added and incubated for 3 h. 100 μl medium
was collected for measuring the fluorescence that was calibrated to a
standard curve to calculate the numbers of attached cells within each
well. After the quantification, cells were fixed with 4% PFA and stained
with DAPI. The nuclei were recorded with a fluorescence microscope.
2.5. 3D cell culture within the fibrin matrix
100 μl fibrin matrix with 2 × 104 cells were made in individual
wells of a 96-well format plate. 200 μl medium was added to each well.
At varied time points after plating, cell morphologies were recorded by
phase-contrast microscopy. The medium was removed and 100 μl fresh
medium with 10 μl Alamar blue reagent were added and incubated for
3 h. 100 μl medium was collected for measuring the fluorescence that
was calibrated to a standard curve to calculate the numbers of cells in
each matrix. The viability of cells within the gel was accessed with a
Live/Dead cell assay kit (Invitrogen) according to the Manufacturer's
instruction.
2.6. Fibrin formulation
To make the fibrin matrix for the above cell culture experiment, the
following components were mixed to the final concentration of fi-
brinogen (γγF1, γγ′F1) at 2.5 mg/mL; thrombin at 1 U/mL; rFXIII at
15.4 U/mL; and pFN at 3.3 mg/mL. F1 and pFN were at a 1 to 1 M ratio.
The mixtures were incubated at 37 °C for 15 min to form the fibrin
matrix.
2.7. SEM and confocal microscopy
Fibrin matrices were made according to the formulation above. For
SEM, samples were fixed with 2.5% glutaraldehyde in 100 mM phosphate
buffer (PH 7.0) at room temperature for 1 h, then at 4 °C overnight.
Samples were rinsed with phosphate buffer twice, 10 min each. Ethanol
dehydration series were performed: 30%, 50%, 70%, 2 × 95%,
2 × 100%, 5 min for each procedure. Then samples were treated with
hexamethyldisilazane (HMDS) as the following: 33% HMDS, 66% HMDS,
2 × 100% HMDS, 2 min for each procedure. Samples were left in 100%
HMDS to air-dry at least overnight before sputter-coated with gold-palla-
dium and imaged with the scanning electron microscope (Hitachi S4700
Field-Emission SEM, Hitachi, Tokyo, Japan) at 10 kV. For confocal mi-
croscopy, samples were fixed with 4% paraformaldehyde (PFA) at 4 °C
overnight, washed with PBS for 3 times, and blocked with 5% goat serum
for 1 h before incubating with primary antibodies at 4 °C overnight. After
extensive washing, secondary antibodies were added and incubated for 2 h
at room temperature. Samples were then washed with PBS before imaged
with confocal microscopy (Nikon A1-R confocal system on a Nikon Eclipse
90i upright fluorescence microscopy).
2.8. Animal research
All animal protocols were approved by the Institutional Animal Care
and Use Committee of the State University of Campinas (protocol
number 4467–1/2017) and the University of Nebraska-Lincoln (pro-
tocol 1571). All experimental procedures were performed following the
guidelines of the Institutional Animal Care and Use Committee of the
University of Campinas and the University of Nebraska-Lincoln and. For
the surgical procedure, mice were anesthetized using intraperitoneal of
xylazine (10 mg/kg) and ketamine (100 mg/kg). Individual doses were
calculated using Labinsane App (Labsincel, 2017). A deep anesthetic
plane was verified by the loss of pedal and corneal reflexes. Two
symmetrical 6-mm full-thickness excisional wounds were created on the
back of each mouse as described previously [60]. Donut-like splints
with an 8 mm diameter of the center hole and 15-mm diameter of the
disc were created. The splint was carefully placed around the wound
and secured to the skin with eight interrupted sutures. After surgery,
animals were maintained in a warm bed for anesthetic recovery. We
applied intraperitoneal injection of tramadol (25 mg/kg) at 0, 12, and
24 h after surgery as an analgesic treatment.
2.9. Mice fibrin sealant treatment
First, we cleaned the unwounded surrounding skin with a saline
solution to remove any traces of biological residue. We sealed the
wound with 50 μL fibrin. The fibrin sealant contained 2.5 mg/mL fi-
brinogen, 3.3 mg/mL fibronectin, 15.4U/mL rFXIIIa, 5 U/mL thrombin,
16 ng/mL VEGF, 5 mM CaCl2 in the Ringer solution. Control animals
received the same amount of CaCl2 and VEGF in the Ringer solution.
The wounds were covered with a sterile transparent Tegaderm dressing.
On days 2, 4, 6, and 9, we cleaned and disinfected the surrounding skin
as described above and reapplied 25 μL fibrin sealant.
2.10. Wound healing process documentation and analysis
Macroscopic evaluation of the healing process was evaluated by
photographs taken at 0, 2, 4, 6, 9, and 11 days after wounding using a
Nikon D610 (Nikon Systems, Inc., Tokyo, Japan) camera with an AF-S
DX NIKKOR 18–55 mm f/3.5–5.6G VR objective. The same distance
(wound to the objective lens), top white fluorescence illumination, and
operator were used on each occasion. We calculate Wound Area as
follows: Wound Area (%) = [(wound area of day 0 - wound area of day
x)/wound area of day 0] × 100. In each group, we use 16 to 20 pho-
tographs per day of analysis. The percentage of wounds with complete
closure was calculated by the number of mice that achieve 100% of
reepithelization over the total of mice. Wound re-epithelization was
examined by ImageJ Software (1.49v).
2.11. Histology
The skin samples containing wounded and unwounded areas were
carefully harvested using an 8 mm biopsy punch. The samples were
fixed in cold 4% (wt/vol) formaldehyde in PBS at 4 °C overnight.
Formaldehyde was discarded, and the tissues were washed 3 times
using PBS 1x. We divided the circular sample in the middle of the circle
to standardize the diameter of the sectioned samples. Then, the samples
were treated with increasing concentration of alcohol (70%, 80%, 95%,
and 100%) followed by xylol and paraffin and finally fixed in paraffin
blocks. We sectioned at 5.0 μm and set 4–6 slices on microscope slides
pretreated with poly-L-lysine. Following this procedure, we stained the
skin sections with hematoxylin and eosin (Sigma). We incubated the
slices with hematoxylin for 30 s, rinsed them in distilled water, in-
cubated them for 30 s with eosin, washed them over in distilled water,
and dehydrated them. For Picrosirius red staining (Picro Sirius Red
Stain Kit, Sigma), we soaked the section for 30 min in distilled water.
Then we incubated the section with Picro-Sirius red solution for 60 min.
Slides were washed with acetic acid solution, and then they were wa-
shed with absolute alcohol. For Masson's Trichrome Staining, we in-
cubated slides in preheated Bouin's Fluid for 60 min and cool for
10 min. We rinsed it in distilled water, and then we incubated in
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Weigert's Iron Hematoxylin for 5 min, Biebrich Scarlet Acid Fuchsin
solution for 15 min, differentiate in the phosphomolybdic acid solution
for 15 min, Aniline Blue solution for 10 min and acetic acid solution for
5 min. Finally, we mounted the slices on Entellan®, digitally captured
the images under bright field microscopy (Leica DM4500B), and pro-
cessed with Leica Application Suite 3v for Full view reconstruction.
2.12. Collagen quantification
To analyze the birefringence patterns, we used microscopy (Nikon®
Corp., Kanagawa, Japan) with two CPL polarized filters. We captured
the images with a 10x or 40x objective and assessed them for collagen
Type III (bright green color) and collagen Type I (red color), with a total
magnification of 100X and 400X. The birefringence for Type I collagen
was dense, strongly birefringent red fibers, whereas Type III collagen
showed thin, green, and softly birefringents [61]. We used Image Pro
Plus (version 4) to measure the stained collagen fibers as the percentage
of total pixels in each wound pictures.
2.13. Full view reconstruction
To increase the precision of evaluation, we reconstructed the whole
skin section using unwounded and wounded images. We used a Nikon
Microscopy to take 10-15 adjacent microphotographs (with 30% of
Fig. 1. a) Reducing SDS-PAGE gel. b) rFXIIIa activity (153.5 ± 19 U/mg) was measured using the 5-(biotinamido) pentylamine incorporation assay. The effect of
rFXIIIa on the viscoelastic and clotting kinetics of γγF1 (c), γγF1+pFN mixture (d), γγ′F1 (e), and γγ′F1:pFN complex (f) were evaluated via TEG assay.
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common areas, 5x objective) and then reconstructed each skin section.
We applied the Photomerge tool with the perspective layout in Adobe
Photoshop (19.1v).
2.14. Transcript expression determination by real-time polymerase chain
reaction (PCR
We used sample aliquots with 5.0 ng RNA for reverse transcription,
applying random hexamer primers and Superscript Moloney-MLV reverse
transcriptase. PCR reactions were performed in real-time using the
TaqMan™ system (Applied Biosystems). The GAPDH gene
(TaqMan™—Applied Biosystems) was employed as the endogenous con-
trol for the reaction to which the expression levels of the gene of interest in
different samples were normalized. After calculating the efficiencies of
amplification, a scatter plot was constructed to define the series of con-
centrations for which the system was competent. Primers for the target
genes were purchased from Applied Biosystems and IDT DNA Technology
against the TGF-1β (Mm.PT.58.43.479940), TNF-α (Mm00443258_ m1),
IL-6 (Mm00446190_m1), VEGF-α (Mm. PT.58.14200306), FGF-1
(Mm.PT.56a.41158563), IGF-1 (Mm.PT.58.5811533), IL-1β n
(Mm00434228_m1), MCP-1 (Mm99999056_m1), IL-10
(Mm01288386_m1), SDF-1 (Mm00445553_m1), ITGA (NM_010577.3),
Plaur (ENSG00000011422), MMP9 (ENSG00000100985), Procr
(ENSG00000101000) FLRT2 (ENSG00000185070), F4/80
(Mm00802529_m1), Cd11b (Mm00434455_m1), iNos
(Mm.PT.5843705194), Cd163 (Mm00474091_m1), Arg1
(Mm.PT.58.8651372) and GAPDH (4352339E). We Used the StepOnePlus
Real-Time PCR System™ (Thermo Fisher Scientific). For transcript quan-
tification, the PCR in real-time were carried out in duplicate in reactions
containing 3 μl of TaqMan Universal PCR Master Mix 2X, 0.25 μl of pri-
mers and probe solution, 0.25 μl of water and 4.0 μl of cDNA. The negative
control used 4.0 μl of water in place of cDNA. The cycling conditions were
as follows: 45 cycles of 95 °C for 2 min, 95 °C for 5 s, and 60 °C for 30 s.
The relative gene expression values were obtained by analyzing the results
in the StepOne™ 2.2.2v (Applied Biosystems).
2.15. Statistical analysis
The data are presented as the mean ± S.D. We used an unpaired t-
test to compare two groups and one-way ANOVA to compare more than
two groups. P < 0.05 was considered statistically significant. We used
GraphPad Prism 6 for Windows 6.01v to perform statistical analysis.
3. Results
3.1. Highly active factor XIII was critical to forming a stable fibrin matrix at
low sealant concentration
Recently, we developed a scalable process to separate γγF1 and
γγ′F1 from human plasma at production scale [8]. We observed that
γγ′F1 and pFN isolated as a noncovalent complex at about 1:1 M ratio
[8]. This complex could be dissociated by passing through a gelatin
affinity column where the pFN was absorbed, and γγ′F1 passed through
the affinity column. We also found that the dissociated γγ′F1 and pFN
Fig. 2. Confocal microscopy fibrin matrices made from γγF1, γγ′F1, 1:1 mixture of γγF1 and pFN, or γγ′F1:pFN complex.
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could quickly re-associate at room temperature [62]. The high purity of
the compositions used in this paper consisting of pFN, γγF1, γγ′F1,
γγ′F1:pFN and a 1:1 mixture of γγF1 and pFN (γγF + pFN) were con-
firmed with reduced SDS-PAGE (Fig. 1a).
The normal concentration of fibrinogen in blood plasma is 2–4 mg/
mL [63]. The natural fibrin clot is strengthened by platelets. In litera-
ture, the fibrin matrix is typically prepared at high protein concentra-
tion, such as> 25 mg/mL F1, to provide sufficient stability and
strength [56]. However, our previous research found human cells ty-
pically did not grow well in fibrin matrix> 9 mg/mL due to the dense
fiber structures [56]. Thus, we recommended using< 9 mg/mL fibrin
for 3D in vitro cell culture, cell delivery, and wound healing application
[56]. However, at such low concentration, it required FXIII-catalyzed
covalent crosslinking to form a stable fibrin matrix [56]. To achieve
this, we expressed a recombinant FXIII [56] with a specific cross-linking
activity of 154 U/mg, which was about 6-fold higher than plasma-de-
rived FXIII (Fig. 1b).
We then tested if stable fibrin matrix could be formed with low F1
concentration using this recombinant FXIIIa, and how the pFN influ-
enced the gelation kinetics and resultant matrix mechanical properties.
Fig. 3. Culturing primary human fibroblasts on top of (a, d) and within 3D fibrin matrices (b, c, e). a) The nuclei of cells attached to fibrin matrices at 3 h. b)
Fibroblasts in 3D fibrin matrices at 2 h and 48 h. c) Live and dead cells at 48 h. d) Cells attached to the fibrin matrices were quantified with alamar blue assay. e) Cells
in 100 μl fibrin matrices at 48 h were quantified with alamar blue assay. Cell numbers are related to the initial seeded cells. **: p < 0.01.
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We used a commercially available, biotherapeutic grade recombinant
thrombin and our rFXIIIa at different concentrations to make fibrin
matrices with γγF1 alone, γγ′F1 alone, γγ′F1:pFN complex, or a 1:1
mixture of γγF1 and pFN. All sealants were formulated at an F1 con-
centration of 2.5 mg/mL with 3.3 mg/mL pFN for both γγ′F1:pFN and
analogous γγF1+pFN mixtures. All groups formed stable matrices with
higher concentrations of rFXIIIa observed to accelerate gelation and
improve the mechanical properties of the fibrin (Fig. 1c–f). Thus, this
highly active rFXIIIa allowed us to use a low concentration fibrin matrix
for our following in vitro cell culture and in vivo studies.
Fig. 4. Culturing primary human umbilical vein endothelial cells (HUVECs) on top of (a, d) and within 3D fibrin matrices (b, c, e). a) HUVECs attached to fibrin
matrices at 3 h. b) HUVECs in 3D fibrin matrices at 30 min and 48 h. Red and black arrows point to apoptotic and live cells respectively. c) Live and dead cells at 48 h.
d) Cells attached to the fibrin matrices were quantified with alamar blue assay. e) Cells in 100 μl fibrin matrices at 48 h were quantified with alamar blue assay. Cell
numbers are related to the initial seeded cells. ***: p < 0.001 and ****: p < 0.0001.
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3.2. 3D fibronectin presentation on the γγ′F1:pFN matrix
We used immunostaining and confocal microscopy to study the
distribution of pFN and F1 in the fibrin matrices (Fig. 2). We found that
all formulations produced similar fibrin fiber networks. Most fibers
were between 100 and 400 nm in diameter while having a similar
degree of branching. Large depots of pFN sporadically occurred within
the fibrin matrix made from the γγF1+pFN mixture. The fibrin made
from the γγ′F1:pFN complex presented pFN throughout the matrix as
nanoclusters superimposed on the continuous γγ′F1 fiber network.
3.3. The 3D fibronectin presentation enhanced the adhesion, migration,
proliferation, and function of healing cells
As previously documented, healing cells interact with the fibrin
provisional matrix through binding fibronectins with their integrin re-
ceptors [32–35]. We hypothesized that the 3D fibronectin nanoclusters
could potentiate the cell-matrix interaction. We first tested the inter-
actions of fibroblasts with these 4 different fibrin matrices. The adhe-
sion of fibroblasts to fibrin made with γγF1, γγ′F1, 1:1 γγF1+pFN
mixture, and γγ′F1:pFN complex were examined through culturing
them on top of the matrix. Cells were allowed to attach to the matrix for
3 h, a time that is sufficient for cellular adhesion. The nuclei of the
attached fibroblasts were stained by DAPI (Fig. 3a). Adhered cells were
also quantified with Alamar blue assay (Fig. 3d). The results showed
that fibroblasts had similar adhesion to these matrices.
For efficient wound healing, the provisional matrix also needs to
support the survival, proliferation, and morphogenesis of both fibro-
blasts and endothelial cells (ECs) in addition to good adhesion. Since
cells in vivo are in the 3D matrix, we also used 3D culture to study these
phenomena in the 4 matrices. Fibroblasts were cultured within the fi-
brin matrix. After 48 h, fibroblasts exhibited extended morphology,
indicating good adhesion in all matrices (Fig. 3b). Fibroblasts survived
well in all matrices, as shown by the live/dead cell staining (Fig. 3c).
However, the numbers of cells in the γγ′F1:pFN complex matrix was
significantly higher (~1.5 fold) than in other matrices (Fig. 3e). These
results showed the γγ′F1:pFN matrix or the 3D pFN presentation pro-
moted the proliferation of fibroblasts.
The interactions of HUVECs with these 4 matrices were also in-
vestigated. HUVECs adhered to the surfaces of all fibrin matrices after
3 h. The numbers of HUVECs adhered to the γγ′F1:pFN matrix was 2
fold of these to the γγF1, γγ′F1, and 1:1 γγF1+pFN mixture matrix,
indicating HUVECs had stronger adhesion to γγ′F1:pFN complex matrix
(Fig. 4a and 4d). After 48 h of culturing in 3D fibrin matrices, HUVECs
in γγF1, γγ′F1, and γγF1+pFN matrix showed spherical morphology,
indicating poor adhesion to the matrices. Some cells showed blebs, a
Fig. 5. (a) Macroscopic wound morphology on different days. Yellow dash line highlights the leading edge of the new epithelium. (b) The percentage of wound area,
and (c) the percentage of mice achieved 100% re-epithelization on different days. 10 mice with 20 wounds were used. *: p < 0.05; *:compared to no treatment
group; *: compared to complex.
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sign of apoptosis (Fig. 4b). The existence of apoptosis was confirmed by
live/dead cell staining (Fig. 4c). HUVECs in γγ′F1:pFN complex matrix
showed no apoptosis. Also, they showed a high level of morphological
sprouting. Quantification found 400% more cells in the γγ′F1:pFN
matrix than other formulations (Fig. 4e). These results showed the
γγ′F1:pFN complex matrix or the 3D pFN presentation significantly
promoted the adhesion, survival, proliferation, and morphogenesis of
HUVECs.
3.4. The 3D fibronectin presentation accelerated skin wound healing in
healthy mice
Based on the in vitro cell culture data, we hypothesized that the
novel matrix could enhance the granulation tissue formation and
wound closure in vivo. We tested this hypothesis in a full-thickness
model in healthy mice. Wounds were treated with γγ′F1:pFN complex,
or γγF1 and pFN mixture. The macroscopic evaluation showed the
Fig. 6. H&E staining of days 2, 6 and 11 wounds. Reprehensive images from 5 animals or 10 wounds.
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γγ′F1:pFN complex significantly speeded up wound closure (Fig. 5a).
Indeed, 50% and 81% of wounds treated with the γγ′F1:pFN complex
achieved full re-epithelization on days 4 and 6, respectively. On the
other hand, 22% and 64% of wounds treated with the mixture achieved
full re-epithelization on days 4 and 6, respectively, and 0% and 30% of
the control wounds (without treatment) achieved full re-epithelization
on day 4 and 6 respectively (Fig. 5c). The microscopic evaluation
confirmed these observations. The migration of epidermal cells was
significantly increased in the γγ′F1:pFN complex treated group just (i.e.,
the leading edge) 2 days post-treatment (Fig. 6a) and showed a com-
plete epithelization over the wound bed on day 6 (Fig. 6b). Histology
also showed dense granulation tissue at the wound center only in the
γγ′F1:pFN complex treated group (Fig. 6b). These data supported that
the novel fibrin sealant/matrix or the 3D pFN presentation promoted
epidermal cell migration, resulting in faster re-epithelization in vivo.
We also evaluated the extracellular matrix formation via histoco-
lorimetric analysis of collagen content (Fig. 7). Total collagen deposi-
tion was identified by Masson's trichrome staining on days 6 and 11
post-wound, period when the highest production of collagen is reached
[64]. Animals treated with γγ′F1:pFN complex or γγF1+pFN mixture
treatments showed no differences in total collagen deposition.
However, the quality of collagen was different. Staining showed dense
and aligned reticular collagen fibers in the γγ′F1:pFN complex group on
day 6, suggesting high-quality granulation tissue (Fig. 7a). The other
treatment groups had a distinctly more sparse and randomly oriented
collagen layer showing less mature granulation tissue.
We evaluated the collagen subtype progression through Picrosirius
Red Staining, which stains collagen III in green and collagen I in red
(Fig. 8). In physiological wound healing, granulation tissue mainly
consists of collagen III in the proliferative phase that gradually changes
to mesh-like collagen I in the remodeling phase. Our data of control
wounds agreed with this (Fig. 8). However, wounds treated with the
γγ′F1:pFN complex on day 6 showed higher collagen I content. Even
more, γγ′F1:pFN complex on day 6 was similar to day 11 of control
group wounds (Fig. 8a–c). On day 11, the γγ′F1:pFN complex group had
the mesh-like collagen organization (Fig. 8b). These data showed the
γγ′F1:pFN complex shifted the granulation formation, collagen re-
modeling about 5 days earlier, and improved the quality of the new
tissue.
We assessed the expression of 20 signature genes associated with
the transitioning between sequences of inflammation, cell migration,
and proliferation [65] that could corroborate macroscopic changes in
Fig. 7. Masson's trichrome staining was done to evaluate the total collagen deposition. Collagen (blue) on the wound bed was much less than the surrounding normal
skin. Reprehensive images from 5 animals or 10 wounds.
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dermal tissue structure. Several statistically significant changes in gene
expression related to the sequence of these processes were observed
among the broad panel of assays presented here (Fig. 9a). For signals
associated primarily with an active inflammatory phase, we observed
by day 2 the γγ′F1:pFN fibrin treatment group had decreased expression
of inflammatory cytokines IL-β1 and IL-10 relative to the other treat-
ment groups(Fig. 9a). Furthermore, by day 6 both relative levels of IL-
β1 and IL-6 had receded to very low relative levels as had the macro-
phage marker F4/80 and monocyte chemoattractant MCP-1. These al-
ready diminished signal profiles related to the inflammatory phase in-
dicates that the inflammatory phase was resolved very early in the
healing process.
The transition from inflammation to signaling needed for kerati-
nocyte migration also occurred early. We found that PROCR, a gene
highly expressed by migrating keratinocytes [66], was increased by the
complex and Mixture treatments on day 6 (Fig. 9a). Moreover, the
complex group showed an early expression of PROCR on day 2. The
Fibronectin Leucine Rich Transmembrane Protein 2 (FLRT2), a cell-cell
adhesion marker for keratinocytes, is highly expressed in the leading
edge during wound healing [65]. FLRT2 is not expressed in healthy skin
epidermis but is expressed during the granulation tissue formation. Our
result showed that the FLRT2 expression was decreased on days 6 and
11 in the γγ′F1:pFN complex group, supporting that the cell migration
was completed before day 6 in the complex group (Fig. 9b). Keratino-
cytes bind to the fibrin matrix using alpha 5 integrins (ITGA5), in order
to migrate. We found ITGA5 expression increased on day 2 and sig-
nificantly decreased on days 6 and 11 for the complex group, sup-
porting that cell migration was completed before day 6 (Fig. 9b). These
data agree with the acceleration of tissue structure observed, such as
the complete re-epithelization and granulation tissue structure found on
day 6 for the γγ′F1:pFN treatment group.
Growth factor signaling is critical for granulation formation. We
found the γγ′F1:pFN treatment decreased expression of TGF-β1, FGF1,
SDF1, VEFG-α and IGF1 genes on day 11, supporting that cell pro-
liferation, granulation tissue formation, and re-epithelization were
completed before day 11 in the γγ′F1:pFN complex group (Fig. 9a).
Even more, IGF1 early declined on day 6, showing the end of the
proliferative phase. Taking all together, animals treated with the
γγ′F1:pFN complex showed a non-inflammatory, non-proliferative, and
non-migrative profile on day 11, suggesting an early resolution of the
wound healing process. In short, our data showed the γγ′F1:pFN com-
plex or the 3D pFN nanoclusters significantly accelerated skin wound
healing in healthy mice.
4. Discussion
The topical application of the fibrin matrix represents a promising
approach to enhance the healing of skin wounds. The natural provi-
sional matrix contains a small number of fibronectins [1,67–69]. Pre-
vious reports have shown that raising the fibronectin content in the
matrix promotes wound healing. For instance, human fetus [70–72]
and invertebrate animals newts [73] heal wounds much faster because
their provision matrices contain much more fibronectins that allow
cells to migrate and proliferate faster. The topical application of pure
soluble fibronectins enhances normal and diabetic wound healing in
animals [70,74–78]. These soluble fibronectins aggregate or attach to
surrounding tissue, but do not form a 3D matrix in the wound bed. A
recent study shows that if processed into a 3D nanofiber scaffold, fi-
bronectins can heal normal skin wound much faster [70]. However,
processing fibronectin nanofibers at a large scale is extremely challen-
ging, limiting their clinical applications.
Both receptor occupancy and clustering are required for integrin
signaling [79–81]. Most recent research shows that one way to boost
integrin signaling is to present fibronectins as nanoclusters that can
cluster the integrin receptors. For example, when cells are cultured on a
uniformly fibronectin-coated substrate, high fibronectin density is re-
quired to trigger the integrin signaling. On the other hand, if fi-
bronectins are patterned into nanoclusters, they trigger a much higher
integrin clustering, signaling, and cell function [81–87]. However,
nano-patterning fibronectin has only be achieved on a 2D substrate to
date. How to pattern fibronectins as nanoclusters in a 3D matrix,
especially on the fibrin nanofibers, and how the 3D nanoscale pre-
sentation influences the cell-matrix interaction and cell signaling are
still unknown.
In our previous paper [8], we reported a bioprocess to separate γγF1
and γγ′F1 from plasma, and we found that γγ′F1 and pFN formed a tight
complex. The γγ′F1 and pFN occur at nearly a 1:1 M ratio in normal
human plasma [9,10,88,89], thus the γγ′F1:pFN complex we isolated
may already exist in human plasma (Fig. 1). The γγ′F1:pFN complex
formed a matrix with fibronectin nanoclusters on the fibrin nanofibers
in the presence of highly active thrombin and rFXIIIa (Fig. 2). We
showed that the fiber diameters and branch points are markedly similar
for all of the fibrins studied. Thus, the fibronectin nanoclusters likely
Fig. 8. Picrosirius red staining on collagen I (red) and III (green) on day 6 (a, c)
and 11 (b, d). Reprehensive images from 5 animals or 10 wounds. Standard
error is presented in (c, d). *:p < 0.05. CTL: control without treatment.
Complex: γγ′F1:pFN complex. Mixture: 1:1 mixture of γγF1 and pFN.
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arose from interactions of pFN with the γ′ tails that are uniquely dis-
played by the γγ′F1 fibrils. Future research should make clear the dy-
namics of forming these nanoclusters, as well as how the sealant
composition affects the matrix structure and properties. This report
successfully reproduced all our previous findings (Figs. 1 and 2),
showing the robustness of the separation process, the γγ′F1:pFN com-
plex, and the novel nanostructures.
We found that the γγ′F1:pFN matrix potentiated the adhesion of key
cells that participate in the wound healing process, including fibroblasts
(Fig. 3) and endothelial cells (Fig. 4) in vitro. This enhanced interaction led
to boosted cell survival, proliferation, migration, and morphogenesis in 3D
culture. This was particularly clear for endothelial cells. Because of the
similarities in core fiber matrix structure among all fibrins studied here, the
enhanced interaction of ECs with γγ′F1:pFN fibrin was likely due to the
pFN nanoclusters. As said, angiogenesis is the rate-limiting step of granu-
lation tissue formation, and granulation tissue formation is the rate-limiting
step of wound healing. Thus the capability to stimulate endothelial cells has
a significant impact on wound healing. The plasma-derived fibrin has a
10:1 ratio of F1 to pFN [7]. This fibrin has been previously shown to
support the colonization of fibroblasts [90], but not EC. FGF-2 and or VEGF
supplementation has been reported as the primary catalyst of EC coloni-
zation in plasma-derived fibrin [91–93]. In contrast, we observed an ac-
celerated EC colonization in the γγ′F1:pFN fibrin without using these
growth factors. Future research should systematically make clear the
Fig. 9. The relative expression of genes related to inflammation (a), and cell migration and proliferation (b). RNA level was normalized to the untreated group.
*:p < 0.05, *:compared to no treatment group; *: compared to complex.
C.P. Jara, et al. Bioactive Materials 5 (2020) 949–962
960
dynamics of cell-matrix interaction and integrin clustering, and how the
interaction alters the global gene expression and cell phenotypes. It is also
very valuable to systematically study how the sealant composition and
matrix structure influence the matrix interaction with the major cell types
of the wound healing process.
Our in vivo studies agreed well with the in vitro cell culture results.
The novel nanostructure significantly accelerated the re-epithelization
(Figs. 5 and 6), granulation tissue formation, and modeling (Figs. 7 and
8). The whole wound healing process was speeded up about 5 days.
Additionally, the quality of the granulation tissue was significantly
improved. This conclusion was supported by the macroscopic mor-
phology (Fig. 5) and microscopic structure analysis (Figs. 6–8) as well
as molecule profiles (Fig. 9). Here we have shown that animals treated
with γγ′F1:pFN complex accelerated cell migration. The previous report
showed that cells at the leading edge in direct contact with the fibrin
matrix do not proliferate actively but migrate to the center of the
wound [65,94]. Animal treated with the γγ′F1:pFN complex modulated
two key membrane proteins that guide cell migration and cell adhesion.
It will be valuable to systematically study the cellular profiles at dif-
ferent time points along the healing process in the future.
As said, large acute skin wounds after surgery, trauma, and burn heal
slowly (e.g., take>1 month) and result in scarred skin that has an ab-
normal appearance, structure, and function. We believe our novel matrix
has a high potential to promote the healing of these wounds. Since all
materials used in our matrix are human proteins, their safety is expected.
Thus our matrix can be quickly translated to bedside once the efficacy and
underlying mechanisms are made clear. Since our matrix is fibrin-based, it
can be used for both hemostasis and enhancing wound healing. In addition
to the acute wounds, our matrix may be used to treat the chronic wound as
well. Skin wounds in the aged population, people with diabetes, obesity,
and vascular diseases present serious difficulties to heal [95,96]. Current
treatments have limited success [95–98]. It will be very valuable to study
treating chronic wounds with our novel sealant in the future.
In conclusion, we confirmed that the 10% γγ′F1 in plasma could be
separated from the 90% γγF1 using our previously reported method [8], as
well as γγ′F1 formed a complex with pFN. We also confirmed that the
γγ′F1:pFN complex formed a fibronectin-nanocluster-on-fibrin-nanofiber
structure. We found that the 3D nano-scale presentation of the FN could
significantly potentiate the cell-matrix interaction in vitro and accelerate the
granulation formation, re-epithelization in a mice skin wound.
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